



The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島成立之有限公司)

(Stock code 股份代號: 3933)

NOTIFICATION LETTER 通知信函

26 September 2022

Dear Shareholder,

The United Laboratories International Holdings Limited (the "Company") **— Notice of Publication of 2022 Interim Report ("Current Corporate Communication")**

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.tul.com.cn and the HKExnews' website at www.hkexnews.hk, or the arranged printed form(s) of Current Corporate Communication is enclosed (if applicable). You may access the Current Corporate Communication by clicking "Investor Relations" on the homepage of our website, then selecting "Financial Reports" and viewing them through Adobe® Reader® or browsing through the HKExnews' website.

Shareholders may at any time choose to receive free of charge Corporate Communications^(Note) either in printed form, or read the website version; and either in English language version only, Chinese language version only or both language versions, notwithstanding any wish to the contrary they have previously conveyed to the Company. If you want to receive another printed version of the Current Corporate Communication, or you would like to change your choice of language or means of receipt of the Company's Corporate Communications in future. Please complete the Change Request Form on the reverse side and send it to the Company c/o Computershare Hong Kong Investor Services Limited (the "Hong Kong Branch Share Registrar"), using the mailing label and need not to affix a stamp when returning (if posted in Hong Kong). Otherwise, please affix an appropriate stamp. The address of Hong Kong Branch Share Registrar is 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong. You may also send an email with a scanned copy of this Form to tul3933.ecom@computershare.com.hk. The Change Request Form may also be downloaded from the Company's website at www.tul.com.cn or the HKExnews' website at www.hkexnews.hk.

Even if you have chosen (or are deemed to have consented) to receive all future Corporate Communications via Website version but for any reason you have difficulty in receiving or gaining access to the Current Corporate Communication, the Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

Should you have any queries relating to any of the above matters, please call the Company's telephone hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays or send an email to tul3933.ecom@computershare.com.hk.

By Order of the Board of
The United Laboratories International Holdings Limited
Leung Wing Hon
Company Secretary

Note: Corporate Communications include but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位股東：

聯邦制藥國際控股有限公司（「本公司」） **— 2022 中期報告（「本次公司通訊文件」）之發佈通知**

本公司的本次公司通訊文件中、英文版本已上載於本公司網站 (www.tul.com.cn) 及香港交易所披露易網站 (www.hkexnews.hk)，歡迎瀏覽。或按安排附上本次公司通訊文件之印刷本（如適用）。請在本公司網站主頁按「投資者關係」一項，再選擇「財務報告」並使用 Adobe® Reader® 開啟查閱或在香港交易所披露易網站瀏覽有關文件。

儘管閣下早前曾向本公司作出公司通訊文件^(附註)收取方式或語言版本的選擇，但仍可以隨時更改有關選擇，轉為以印刷本或網上方式收取及只收取英文印刷本、或只收取中文印刷本；或同時收取中、英文印刷本，費用全免。如閣下欲收取本次公司通訊文件之另一語言印刷本，或欲選擇有別於閣下所選擇的公司通訊語言版本或收取方式，以更改日後收取公司通訊文件之語言版本及收取途徑之選擇。請閣下填妥在本函背面的變更申請表格，並使用隨附之郵寄標籤寄回，而毋須貼上郵票（如在香港投寄）；否則，請貼上適當的郵票，申請表格請寄回香港中央證券登記有限公司（「香港股份過戶登記分處」），地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。你亦可把已填妥之變更申請表格的掃描副本電郵至 tul3933.ecom@computershare.com.hk。變更申請表格亦可於本公司網站 (www.tul.com.cn) 或香港交易所披露易網站 (www.hkexnews.hk) 內下載。

股東如已選擇以網上方式收取日後公司通訊文件（或被視為已同意以網上方式收取）但因任何理由未能閱覽載於網站的本次公司通訊文件，股東只要提出要求，我們將盡快向閣下寄上所要求的有關文件的印刷版本，費用全免。

如對本函內容有任何疑問，請致電本公司電話熱線 (852) 2862 8688，辦公時間為星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正或電郵至 tul3933.ecom@computershare.com.hk。

承董事會命
聯邦制藥國際控股有限公司
公司秘書
梁永康

2022 年 9 月 26 日

附註：公司通訊文件包括但不限於：(a) 董事會報告、年度財務報表連同核數師報告及如適用，財務摘要報告；(b) 中期報告及如適用，中期摘要報告；(c) 會議通告；(d) 上市文件；(e) 通函；及(f) 委任代表表格。